Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
It is found that UFL1-deficient CD8 T cells undergo exhaustion during acute viral infection, and the findings suggest that exhaustion in UFL1-deficient CD8 T cells is PD1-independent.
Abstract
Cytotoxic CD8 T cells play a crucial role in eliminating infections and cancer. However, chronic antigen exposure induces their development into exhausted T (TEX) cells. TEX cells exhibit increased inhibitory receptors or checkpoints expression, defective effector functions and thus unable to eliminate the virus-infected cells and cancers. Antibodies inhibiting signaling through checkpoints PD1 or CTLA4 (immune checkpoint blockade or ICB) induce differentiation of TEX cells into effectors that eliminate cancer and viral infected cells. PD1 blockade is the leading ICB against several tumor types. However, > 50% of the cancer patients either do not respond or get durable benefits from PD1 blockade. Therefore, there is an urgent need to understand the PD1-independent mechanism to improve immunotherapy against tumors resistant to PD1 blockade.
In order to address the role of UFL-1 in CD8 T cell exhaustion, we used LCMV acute and chronic infection models in control and CD4 specific UFL-1 knockout mice. Different subset of CD8 T cells and their differentiation status and functional response upon activation were analyzed using flow cytometry and ScRNA-seq.
Acute exposure to antigens, is not known to cause T cell exhaustion. We found that UFL1-deficient CD8 T cells undergo exhaustion during acute viral infection. During chronic antigen presence, such as in tumor models and chronic viral infections, UFL1 deficiency worsens CD8 T cell exhaustion. Additionally, the PD1 blockade fails to improve the functionality of UFL1-deficient TEX cells. Consistent with this, UFL1 expression in tumor-infiltrating CD8 T cells is positively correlated with the progression-free survival of melanoma patients treated with PD1 blockade.
These findings suggest that exhaustion in UFL1-deficient CD8 T cells is PD1-independent. Therefore, understanding how UFL1 prevents T cell exhaustion would help discover new ways to improve immunotherapies, especially for cancers that do not respond to PD1 blockade.
NIH Funding - NIAID00054
Immune Response Regulation: Molecular Mechanisms (IRM)
Immune checkpoint blockade (ICB) provides durable therapeutic responses across multiple cancer types. Although crosstalk between T cells and conventional type 1 dendritic cells (cDC1s) is essential, the contribution of other antigen-presenting cells (APCs) to ICB-induced tumor rejection remains unclear. To address...
Hitoki Arisato, Takurou Noguchi, Akihiko Shiiya et al.· Cancer Immunology and Immuno...· 0 citations
Blockade of inhibitory PD-1 signaling on T cells is a cornerstone of cancer immunotherapy, with current strategies targeting PD-1 or its ligand PD-L1. However, PD-1 engages an alternative ligand, PD-L2, whose role in tumor immunity remains poorly defined. Here, we show that PD-L2 is upregulated on intratumoral CCR7⁺ co...
Immunotherapy transformed cancer treatment, yet precise correlates of response remain to be defined. While intratumoral follicular helper like (Tfhl) CD4 T cells and IgG1+ B cells have been associated with improved outcomes to PD-1 blockade for hepatocellular carcinoma (HCC), their mechanisms contributing to response a...
A. Vaidya, Étienne Humblin, Nataliya Prokhnevska et al.· bioRxiv· 0 citations
The identification of a T cell receptor targeting a clinically relevant HBV epitope and ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.
Wei Xu, Jie Guo, Xue Cao et al.· Nature Immunology· 0 citations
Immune checkpoint blockade has revolutionized cancer therapy; however, numerous tumors remain resistant by adopting cellular states that impede immune recognition. In this study, we identify the nerve growth factor receptor (NGFR) as a regulator of immune evasion in head and neck squamous cell carcinoma (HNSCC). Geneti...
J. García-Agulló, V. Santos, B. Majem et al.· bioRxiv· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.